Literature DB >> 1313928

Transactivation of human immunodeficiency virus type 1 long terminal repeat-directed gene expression by the human foamy virus bel1 protein requires a specific DNA sequence.

A H Lee1, K J Lee, S Kim, Y C Sung.   

Abstract

Human foamy virus (HFV) encodes the transcriptional transactivator bel1. The bel1 protein transactivates HFV long terminal repeat (LTR)-directed gene expression by recognizing a region in U3. It also transactivates human immunodeficiency virus type 1 (HIV-1) LTR-directed gene expression in transient transfection assays. To identify the specific region in HIV-1 LTR responsible for bel1 action, we examined the effect of bel1 on chloramphenicol acetyltransferase (CAT) gene expression in transfected cells with a series of mutant HIV-1 LTR/CAT plasmids. The region between -158 and -118 from the transcription initiation site, immediately upstream of the core enhancer element, was identified as responsible for the transactivation by bel1. In addition, bel1 transactivated a heterologous promoter when this region was positioned upstream of it in the sense and antisense orientations. Optimal transactivation of the HIV-1 LTR by bel1 did not require an intact TAR sequence, suggesting that the binding of tat to the TAR sequence is not a prerequisite for bel1 function in HIV-1 LTR-directed gene expression. In the region of the HIV-1 LTR that is necessary for the bel1-mediated transactivation, we have found a sequence which is conserved between HIV-1 and HFV. Our results suggest that the bel1 action on HIV-1 seems to be mediated by a specific DNA sequence which is shared by both the HIV-1 LTR and HFV LTR.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1313928      PMCID: PMC241094     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

Review 1.  HIV TAR: an RNA enhancer?

Authors:  P A Sharp; R A Marciniak
Journal:  Cell       Date:  1989-10-20       Impact factor: 41.582

Review 2.  HIV trans-activation and transcription control mechanisms.

Authors:  K A Jones
Journal:  New Biol       Date:  1989-11

3.  The pX protein of HTLV-I is a transcriptional activator of its long terminal repeats.

Authors:  B K Felber; H Paskalis; C Kleinman-Ewing; F Wong-Staal; G N Pavlakis
Journal:  Science       Date:  1985-08-16       Impact factor: 47.728

4.  Herpes simplex virus type-1 can reactivate transcription of latent human immunodeficiency virus.

Authors:  J D Mosca; D P Bednarik; N B Raj; C A Rosen; J G Sodroski; W A Haseltine; P M Pitha
Journal:  Nature       Date:  1987 Jan 1-7       Impact factor: 49.962

5.  Transactivation of human immunodeficiency virus promoter by human herpesvirus 6.

Authors:  R T Horvat; C Wood; N Balachandran
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

6.  An inducible transcription factor activates expression of human immunodeficiency virus in T cells.

Authors:  G Nabel; D Baltimore
Journal:  Nature       Date:  1987 Apr 16-22       Impact factor: 49.962

7.  Analysis of Sp1 in vivo reveals multiple transcriptional domains, including a novel glutamine-rich activation motif.

Authors:  A J Courey; R Tjian
Journal:  Cell       Date:  1988-12-02       Impact factor: 41.582

8.  Molecular cloning of the genome of human spumaretrovirus.

Authors:  A Rethwilm; G Darai; A Rösen; B Maurer; R M Flügel
Journal:  Gene       Date:  1987       Impact factor: 3.688

9.  A transcriptional enhancer sequence of HTLV-I is responsible for trans-activation mediated by p40 chi HTLV-I.

Authors:  J Fujisawa; M Seiki; M Sato; M Yoshida
Journal:  EMBO J       Date:  1986-04       Impact factor: 11.598

10.  Nucleotide sequence analysis of the env gene and its flanking regions of the human spumaretrovirus reveals two novel genes.

Authors:  R M Flügel; A Rethwilm; B Maurer; G Darai
Journal:  EMBO J       Date:  1987-07       Impact factor: 11.598

View more
  21 in total

Review 1.  Mechanism of action of regulatory proteins encoded by complex retroviruses.

Authors:  B R Cullen
Journal:  Microbiol Rev       Date:  1992-09

2.  Expression and maturation of human foamy virus Gag precursor polypeptides.

Authors:  M L Giron; S Colas; J Wybier; F Rozain; R Emanoil-Ravier
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

3.  In vitro infection of primary and retrovirus-infected human leukocytes by human foamy virus.

Authors:  J A Mikovits; P M Hoffman; A Rethwilm; F W Ruscetti
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

4.  Increase in the basal transcriptional activity of the human foamy virus internal promoter by the homologous long terminal repeat promoter in cis.

Authors:  M Löchelt; M Aboud; R M Flügel
Journal:  Nucleic Acids Res       Date:  1993-09-11       Impact factor: 16.971

5.  Transcriptional mapping of the 3' end of the bovine syncytial virus genome.

Authors:  R W Renshaw; J W Casey
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

6.  Human foamy virus genome possesses an internal, Bel-1-dependent and functional promoter.

Authors:  M Löchelt; W Muranyi; R M Flügel
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

Review 7.  Transgenic and knockout mice in the study of neurodegenerative diseases.

Authors:  A Aguzzi; S Brandner; S Marino; J P Steinbach
Journal:  J Mol Med (Berl)       Date:  1996-03       Impact factor: 4.599

8.  Functional domains of the simian foamy virus type 1 transcriptional transactivator (Taf).

Authors:  A Mergia; L W Renshaw-Gegg; M W Stout; R Renne; O Herchenröeder
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

9.  Further characterization of equine foamy virus reveals unusual features among the foamy viruses.

Authors:  Charles-Henri Lecellier; Manuel Neves; Marie-Lou Giron; Joelle Tobaly-Tapiero; Ali Saïb
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  The carboxy-terminal transcription enhancement region of the human spumaretrovirus transactivator contains discrete determinants of the activator function.

Authors:  L K Venkatesh; G Chinnadurai
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.